The emerging role of computational design in peptide macrocycle drug discovery
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Drug discovery is a laborious process with rising cost per new drug. Peptide macrocycles are promising therapeutics, though conformational flexibility can reduce target affinity and specificity. Recent computational advancements address this problem by enabling rational design of rigidly folded peptide macrocycles.Areas Covered This review summarizes currently approved peptide macrocycle therapeutics and discusses advantages of mesoscale drugs over small molecules or protein therapeutics. It describes the history, rationale, and state of the art of computational tools, such as Rosetta, that allow the design of rigidly structured peptide macrocycles. The emerging pipeline for designing peptide macrocycle drugs is described, including current challenges in designing permeable molecules that can emulate the chameleonic behavior of natural macrocycles. Prospects for reducing computational cost and improving accuracy with emerging computational technologies are also discussed.Expert opinion To embrace computational design of peptide macrocycle drugs, we must shift current attitudes regarding the role of computation in drug discovery, and move beyond Lipinski’s rules. This technology has the potential to shift failures to earlier in silico stages of the drug discovery process, improving success rates in costly clinical trials. Given the available tools, now is the time for drug developers to incorporate peptide macrocycle design into drug discovery pipelines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Quantum Computing in the NISQ era and beyond
Preskill, J. (2018) · Quantum · doi:10.22331/q-2018-08-06-79 · Cited by 8,830
DrugBank 5.0: a major update to the DrugBank database for 2018
Wishart, D. S., Feunang, Y. D., Guo, A. C., Lo, E. J., Marcu, A., Grant, J. R., Sajed, T., Johnson, D., Li, C., Sayeeda, Z., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1037 · Cited by 8,404
DrugBank: a comprehensive resource for in silico drug discovery and exploration
Wishart, D. S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj067 · Cited by 3,892
From Levinthal to pathways to funnels
Dill, K. A., & Chan, H. S. (1997) · Nature Structural & Molecular Biology · doi:10.1038/nsb0197-10 · Cited by 2,293 · cited 1×
“…accurate and precise calculations of enthalpies, but much of the conformational and binding energy for a drug molecule comes from the hydrophobic effect, which is entropic in origin and often necessitates either large-scale sampling of water, or limited-accuracy implicit solvation models [149,150].”
BackgroundDiagnosing the decline in pharmaceutical R&D efficiency
Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3681 · Cited by 1,981 · cited 1×
“Despite major scientific advancements to the drug development process, and rising investment of person-hours, money, and resources, the number of new molecular entities approved for clinical use each year has remained steady [3,4], meaning that the cost of introducing a new drug is rising [5].”
BackgroundAtomic-level characterization of the structural dynamics of proteins
Shaw, D. E., Maragakis, P., Lindorff-Larsen, K., Piana, S., Dror, R. O., Eastwood, M. P., Bank, J. A., Jumper, J. M., Salmon, J. K., Shan, Y., et al. (2010) · Science · doi:10.1126/science.1187409 · Cited by 1,923
The Rosetta All-Atom Energy Function for Macromolecular Modeling and Design
Alford, R. F., Leaver-Fay, A., Jeliazkov, J. R., O’Meara, M. J., DiMaio, F. P., Park, H., Shapovalov, M. V., Renfrew, P. D., Mulligan, V. K., Kappel, K., et al. (2017) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.7b00125 · Cited by 1,532
Self-citationContemporary strategies for peptide macrocyclization
White, C. J., & Yudin, A. K. (2011) · Nature Chemistry · doi:10.1038/nchem.1062 · Cited by 1,088
Shapovalov, M. V., & Dunbrack, R. L. (2011) · Structure · doi:10.1016/j.str.2011.03.019 · Cited by 1,000 · cited 1×
“The observed distribution across PDB structures of backbone and side-chain conformations for each canonical amino acid is used both to construct knowledge-based potentials for amino acid conformation and to guide conformational sampling [97,110,111].”
Kwekkeboom, D. J., Teunissen, J. J., Bakker, W. H., Kooij, P. P., de Herder, W. W., Feelders, R. A., van Eijck, C. H., Esser, J.-P., Kam, B. L., & Krenning, E. P. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.066 · Cited by 657
Cited by
Hsueh, S. C. C., Aina, A., Roman, A. Y., Cashman, N. R., Peng, X., & Plotkin, S. S. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00567 · Cited by 8
Metadata
- Authors
- Mulligan, V. K.
- Venue
- Expert Opinion on Drug Discovery
- Publisher
- Informa UK Limited
- Published
- 2020-04-28
- Volume
- 15
- Issue
- 7
- Pages
- 833-852
- ISSN
- 1746-0441 (ISSN-L)
- 1746-045X
- OpenAlex
- W3017609301
- Cited by
- 58
- References
- 15
- FWCI
- 1.87
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The emerging role of computational design in peptide macrocycle drug discovery. https://app.cochat.ai/papers/10.1080/17460441.2020.1751117
- The paper
- Mulligan, V. K. (2020). The emerging role of computational design in peptide macrocycle drug discovery. Expert Opinion on Drug Discovery. https://doi.org/10.1080/17460441.2020.1751117
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.